Barclays Maintains Underweight on Gilead Sciences, Raises Price Target to $60
Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Underweight and raises the price target from $56 to $60.
Gilead’s Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer
The FDA has accepted for review Gilead Sciences Inc’s (NASDAQ:GILD) Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor…
A Bullish Sign Appears On Gilead Sciences’s Chart
If history is any guide, there may be good fortune ahead for shares of Gilead Sciences (NASDAQ:GILD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Why This Gilead Analyst Believes The Stock Is Highly Undervalued
While there is increased visibility for Gilead Sciences, Inc’s (NASDAQ: GILD) HIV franchise, its emerging oncology franchise is not well reflected in its valuation, according to JPMorgan.
JP Morgan Upgrades Gilead Sciences to Overweight, Raises Price Target to $80
JP Morgan analyst Chris Schott upgrades Gilead Sciences (NASDAQ:GILD) from Neutral to Overweight and raises the price target from $72 to $80.
Gilead’s Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs.
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Merck & Co Inc (NYSE:MRK) will initiate a new Phase 3 program with once-daily islatravir to treat people with HIV-1 infection. …
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Truist Securities Maintains Hold on Gilead Sciences, Raises Price Target to $76
Truist Securities analyst Robyn Karnauskas maintains Gilead Sciences (NASDAQ:GILD) with a Hold and raises the price target from $71 to $76.
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
As part of President Joe Biden’s executive order to beef up U.S. biomanufacturing, the U.S. Department of Health and Human…